Effects of Chronic Central Nervous System Administration of Agouti-Related Protein in Pair-Fed Animals

  1. Caroline J. Small,
  2. Min S. Kim,
  3. Sarah A. Stanley,
  4. John R.D. Mitchell,
  5. Kevin Murphy,
  6. David G.A. Morgan,
  7. Mohammad A. Ghatei and
  8. Stephen R. Bloom
  1. From the Department of Metabolic Medicine, Division of Investigative Sciences, Imperial College School of Medicine, Hammersmith Hospital, London, U.K.
  1. Address correspondence and reprint requests to Dr. Stephen R. Bloom, Department of Metabolic Medicine, Division of Investigative Sciences, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London, W12 ONN, U.K. Email: s.bloom{at}ic.ac.uk .

Abstract

The melanocortin receptor (MC3-R and MC4-R) antagonist, agouti-related protein (AGRP), is a potent stimulant of food intake. We examined the effect of chronic intracerebroventricular (ICV) AGRP treatment on energy metabolism and pituitary function in ad libitum fed rats and rats administered AGRP and then pair-fed to a saline control group. Chronic ICV AGRP (83-132) administration (1 nmol/day for 7 days) significantly increased food intake and body weight in ad libitum fed animals compared with saline-treated controls (body weight on day 7: 272 ± 6 [saline] vs. 319 ± 8 g [AGRP ad libitum fed]; P < 0.001). A significant increase in the epididymal fat pad weight, interscapular brown adipose tissue (BAT) weight, and plasma leptin was also observed in the ad libitum fed group. In the AGRP pair-fed group, a significant increase in the epididymal fat pad weight, BAT weight, and plasma leptin was again observed, suggesting that AGRP caused metabolic changes independent of increased food intake. BAT uncoupling protein 1 (UCP-1) content was significantly decreased compared with saline controls in both the AGRP ad libitum fed (21 ± 8% of saline control; P < 0.01) and AGRP pair-fed groups (24 ± 7% of saline control; P < 0.01). Plasma thyroid-stimulating hormone (TSH) was significantly suppressed compared with saline controls in both the AGRP ad libitum fed and AGRP pair-fed groups (3.5 ± 0.3 [saline] vs. 2.7 ± 0.4 [AGRP ad libitum fed] vs. 2.1 ± 0.2 ng/ml [AGRP pairfed]; P < 0.01). This study demonstrates that independent of its orexigenic effects, chronic AGRP treatment decreased BAT UCP-1, suppressed plasma TSH, and increased fat mass and plasma leptin, suggesting that it may play a role in energy expenditure.

Footnotes

  • M.S.K. and S.A.S. contributed equally to this study.

  • α-MSH, α-melanocyte-stimulating hormone; AGRP, agouti-related protein; Ang-II, angiotensin II; BAT, brown adipose tissue; BSA, bovine serum albumin; ECL, enhanced chemiluminescence; FSH, follicle-stimulating hormone; HPA, hypothalamopituitary adrenal; ICV, intracerebroventricular; ir, immunoreactivity; LH, luteinizing hormone; LRHR, LH-releasing hormone; MC3-R, melanocortin 3 receptor; MC4-R, melanocortin 4 receptor; NPY, neuropeptide Y; POMC, proopiomelanocortin; PVN, paraventricular nucleus; RIA, radioimmunoassay; SHBG, sex hormone-binding globulin; TBS, Tris-buffered saline; TEMED, N,N,N′,N′-tetramethylethylene diamine; TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; UCP-1, uncoupling protein 1; WAT, white adipose tissue.

    • Accepted October 6, 2000.
    • Received February 24, 2000.
« Previous | Next Article »Table of Contents